

References for the November 2024 *Basically Speaking* Article “Looking in All Directions: Exploring a New Horizon for PCOS Therapeutics” by Kathryn R. Brewer

1. N. Mast *et al.*, Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. *J Biol Chem* **286**, 5607-5613 (2011).
2. R. P. Crespo, T. Bachegea, B. B. Mendonca, L. G. Gomes, An update of genetic basis of PCOS pathogenesis. *Arch Endocrinol Metab* **62**, 352-361 (2018).
3. N. M. DeVore, E. E. Scott, Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. *Nature* **482**, 116-119 (2012).
4. J. Lo *et al.*, Structural basis for the functional roles of critical residues in human cytochrome p450 aromatase. *Biochemistry* **52**, 5821-5829 (2013).
5. T. Li, P. Stephen, D. W. Zhu, R. Shi, S. X. Lin, Crystal structures of human 17beta-hydroxysteroid dehydrogenase type 1 complexed with estrone and NADP(+) reveal the mechanism of substrate inhibition. *FEBS J* **286**, 2155-2166 (2019).
6. C. K. Welt, J. M. Duran, Genetics of polycystic ovary syndrome. *Semin Reprod Med* **32**, 177-182 (2014).
7. J. M. McAllister, R. S. Legro, B. P. Modi, J. F. Strauss, 3rd, Functional genomics of PCOS: from GWAS to molecular mechanisms. *Trends Endocrinol Metab* **26**, 118-124 (2015).
8. J. Jumper *et al.*, Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589 (2021).
9. T. Zore, N. V. Joshi, D. Lizneva, R. Azziz, Polycystic Ovarian Syndrome: Long-Term Health Consequences. *Semin Reprod Med* **35**, 271-281 (2017).
10. R. J. Rodgers *et al.*, Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. *Endocr Connect* **8**, R71-R75 (2019).
11. P. Kempegowda, E. Melson, K. N. Manolopoulos, W. Arlt, M. W. O'Reilly, Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. *Ther Adv Endocrinol Metab* **11**, 2042018820934319 (2020).
12. A. Pani *et al.*, From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management. *Int J Endocrinol* **2020**, 6276187 (2020).
13. J. Melin *et al.*, Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. *J Clin Endocrinol Metab* **109**, e817-e836 (2024).
14. M. Ismayilova, S. Yaya, 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada. *Int Health* **15**, 56-66 (2023).
15. M. Dapas, A. Dunaif, The contribution of rare genetic variants to the pathogenesis of polycystic ovary syndrome. *Curr Opin Endocr Metab Res* **12**, 26-32 (2020).
16. V. L. Nelson, R. S. Legro, J. F. Strauss, 3rd, J. M. McAllister, Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. *Mol Endocrinol* **13**, 946-957 (1999).
17. J. K. Wickenheisser *et al.*, Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. *J Clin Endocrinol Metab* **85**, 2304-2311 (2000).
18. V. L. Nelson *et al.*, The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. *J Clin Endocrinol Metab* **86**, 5925-5933 (2001).

19. J. K. Wickenheisser *et al.*, Cholesterol side-chain cleavage gene expression in theca cells: augmented transcriptional regulation and mRNA stability in polycystic ovary syndrome. *PLoS One* **7**, e48963 (2012).
20. R. A. Harris, J. M. McAllister, J. F. Strauss, 3rd, Single-Cell RNA-Seq Identifies Pathways and Genes Contributing to the Hyperandrogenemia Associated with Polycystic Ovary Syndrome. *Int J Mol Sci* **24**, (2023).
21. H. Zhao, Y. Lv, L. Li, Z. J. Chen, Genetic Studies on Polycystic Ovary Syndrome. *Best Pract Res Clin Obstet Gynaecol* **37**, 56-65 (2016).
22. W. L. Miller, R. J. Auchus, The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. *Endocr Rev* **32**, 81-151 (2011).
23. S. Alesi *et al.*, Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. *EClinicalMedicine* **63**, 102162 (2023).
24. A. Wawrzekiewicz-Jalowicka *et al.*, In Search of New Therapeutics-Molecular Aspects of the PCOS Pathophysiology: Genetics, Hormones, Metabolism and Beyond. *Int J Mol Sci* **21**, (2020).
25. Y. Liu *et al.*, Artemisinin ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction. *Science* **384**, eadk5382 (2024).
26. H. Reyburn, New WHO guidelines for the treatment of malaria. *BMJ* **340**, c2637 (2010).
27. K. Szczepanowska, A. Trifunovic, Mitochondrial matrix proteases: quality control and beyond. *FEBS J* **289**, 7128-7146 (2022).
28. E. Harris, Antimalarial Drug Could Also Treat, Relieve PCOS. *JAMA* **332**, 274 (2024).
29. E. Stener-Victorin, Remedy hope for polycystic ovary syndrome. *Science* **384**, 1174-1175 (2024).
30. O. Tysoe, Artemisinins as a promising treatment for polycystic ovary syndrome. *Nat Rev Endocrinol* **20**, 508 (2024).
31. Z. Y. Zhang *et al.*, [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]. *Zhong Xi Yi Jie He Xue Bao* **6**, 134-138 (2008).
32. C. von Hagens *et al.*, Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). *Phytomedicine* **54**, 140-148 (2019).
33. Y. Huang, Y. Yang, G. Liu, M. Xu, New clinical application prospects of artemisinin and its derivatives: a scoping review. *Infect Dis Poverty* **12**, 115 (2023).
34. D. C. Leucuta, D. Anton, O. Almasan, Estrogen Hormones' Implications on the Physiopathology of Temporomandibular Dysfunction. *J Clin Med* **13**, (2024).
35. L. M. Semeniuk, V. K. Likhachov, T. Y. Yuzvenko, C. Dobrovolska Lcapital Em, O. G. Makarov, Risk markers of reproductive loss in women with hyperandrogenism. *Wiad Lek* **71**, 1550-1553 (2018).
36. A. E. Schindler, Progesterone deficiency and endometrial cancer risk. *Maturitas* **62**, 334-337 (2009).
37. R. F. Savaris *et al.*, Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. *J Clin Endocrinol Metab* **96**, 1737-1746 (2011).
38. Z. Q. Shen, H. T. Zhu, J. F. Lin, Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. *Obstet Gynecol* **112**, 465-467 (2008).

39. B. G. Chittenden, G. Fullerton, A. Maheshwari, S. Bhattacharya, Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. *Reprod Biomed Online* **19**, 398-405 (2009).
40. P. Chakraborty *et al.*, Recurrent pregnancy loss in polycystic ovary syndrome: role of hyperhomocysteinemia and insulin resistance. *PLoS One* **8**, e64446 (2013).
41. L. Gomez, J. R. Kovac, D. J. Lamb, CYP17A1 inhibitors in castration-resistant prostate cancer. *Steroids* **95**, 80-87 (2015).
42. T. Kulasegaran, N. Oliveira, Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management. *Curr Treat Options Oncol* **25**, 914-931 (2024).
43. A. W. Hahn, C. S. Higano, M. E. Taplin, C. J. Ryan, N. Agarwal, Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. *Am Soc Clin Oncol Educ Book* **38**, 363-371 (2018).
44. R. J. Auchus *et al.*, Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. *J Clin Endocrinol Metab* **99**, 2763-2770 (2014).
45. H. Bonnefoi *et al.*, A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Ann Oncol* **27**, 812-818 (2016).
46. S. S. Udhane, B. Dick, Q. Hu, R. W. Hartmann, A. V. Pandey, Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis. *Biochem Biophys Res Commun* **477**, 1005-1010 (2016).
47. S. Decamps, R. Lis, P. Ekanayake, Abiraterone-Induced Endocrinopathies. *JCEM Case Rep* **1**, luad039 (2023).
48. A. Prete, R. J. Auchus, R. J. Ross, Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. *Eur J Endocrinol* **186**, R1-R14 (2021).
49. C. Fehl *et al.*, Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. *J Med Chem* **61**, 4946-4960 (2018).
50. M. A. Pinto-Bazurco Mendieta *et al.*, Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. *J Med Chem* **51**, 5009-5018 (2008).
51. S. Bonomo *et al.*, Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. *Sci Rep* **6**, 29468 (2016).
52. N. S. Sucman *et al.*, Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity. *Steroids* **210**, 109475 (2024).
53. T. M. Wrobel *et al.*, Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis. *Biomolecules* **13**, (2023).
54. B. E. Blass *et al.*, Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome. *Bioorg Med Chem Lett* **26**, 5825-5829 (2016).
55. O. U. Rehman *et al.*, The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. *Clin Genitourin Cancer* **22**, 483-490 e485 (2024).
56. M. Jarman *et al.*, Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. *J Med Chem* **33**, 2452-2455 (1990).
57. C. P. Owen, I. Shahid, W. Y. Lee, S. Ahmed, Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as potent inhibitors of 17 α -hydroxylase/17,20-lyase (P45017 α) derived from rat testicular microsomes. *Bioorg Med Chem Lett* **20**, 5345-5348 (2010).

58. B. CA *et al.*, Identification of Potential Cytochrome p450c 17 Alpha Inhibitors for the Treatment of PCOS via Scaffold Hopping and Fragment-Based De-Novo Drug Design *Journal of Drug Design and Medicinal Chemistry* **10**, 31-44 (2024).
59. T. Yu *et al.*, Exploring the Chemical Space of CYP17A1 Inhibitors Using Cheminformatics and Machine Learning. *Molecules* **28**, (2023).
60. T. M. Wrobel *et al.*, Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment. *J Med Chem* **66**, 6542-6566 (2023).
61. T. Kaku *et al.*, Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. *Bioorg Med Chem* **19**, 6383-6399 (2011).
62. R. A. Madan *et al.*, Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. *Clin Genitourin Cancer* **18**, 258-267 e251 (2020).
63. M. Rampurwala *et al.*, Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. *Invest New Drugs* **35**, 87-94 (2017).
64. A. Bardia *et al.*, Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. *Breast Cancer Res Treat* **171**, 111-120 (2018).
65. M. Dapas *et al.*, Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. *PLoS Med* **17**, e1003132 (2020).
66. K. Van Der Ham *et al.*, Clustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome. *The Journal of Clinical Endocrinology & Metabolism*, (2024).
67. S. Kenigsberg *et al.*, Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. *Molecular Human Reproduction* **15**, 89-103 (2008).
68. J. Cai *et al.*, Association of Fat Mass and Skeletal Muscle Mass with Cardiometabolic Risk Varied in Distinct PCOS Subtypes: A Propensity Score-Matched Case-Control Study. *Journal of Clinical Medicine* **13**, 483 (2024).
69. W. Ye, T. Xie, Y. Song, L. Zhou, The role of androgen and its related signals in PCOS. *Journal of Cellular and Molecular Medicine* **25**, 1825-1837 (2021).
70. R. Kaur, T. Kaur, N. Sudhir, A. Kaur, Association Analysis of CYP11A1 Variants with Polycystic Ovary Syndrome: a Case-Control Study from North India. *Reproductive Sciences* **28**, 2951-2960 (2021).